Paradoxical dyshidrosis following bimekizumab treatment for severe recalcitrant psoriasis
Open Access
- 8 November 2025
- journal article
- case report
- Published by Elsevier in JAAD Case Reports
- Vol. 67, 152-154
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseasesNature Communications, 2024
- Risk of Paradoxical Eczema in Patients Receiving Biologics for PsoriasisJAMA Dermatology, 2024
- A Case Series of Patients With Eczematous Eruptions Following IL-17 Inhibitor Treatment for Psoriasis VulgarisJournal Of Drugs In Dermatology, 2023
- IL-17 and -23 Inhibitors for the Treatment of PsoriasisEMJ Allergy & Immunology, 2023
- Review of bimekizumab in the treatment of psoriasisHuman Vaccines & Immunotherapeutics, 2022
- Psoriasis: a brief overviewClinical Medicine, 2021
- Acrodermatitis continua of Hallopeau: clinical perspectivesPsoriasis: Targets and Therapy, 2019
- Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global AssessmentJournal of the American Academy of Dermatology, 2004